DGI:Knochen-, Gelenks- und Protheseninfektionen/Quellen - Revision history

imported>Bestem at 22:58, 2 May 2022

2022-05-02T22:58:21Z

← Older revision		Revision as of 22:58, 2 May 2022
Line 207:		Line 207:

	Tande AJ, Gomez-Urena EO, Berbari EF et al: Management of prosthetic joint infection. Infect Dis Clin N AM 2017; 31: 237-252,		Tande AJ, Gomez-Urena EO, Berbari EF et al: Management of prosthetic joint infection. Infect Dis Clin N AM 2017; 31: 237-252,


	Taylor DG, Buchholz AL, Sure DR, Buell TJ, Nguyen JH, Chen CJ, Diamond JM, Washburn PA, Harrop J, Shaffrey <span class="mw-lingo-term" data-lingo-term-id="3ba0f40775d6d6ace27ef929f5be3cdf" data-hasqtip="3" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;">CI</span>, Smith JS. Presentation and Outcomes After Medical and Surgical Treatment Versus Medical Treatment Alone of Spontaneous Infectious Spondylodiscitis: A Systematic Literature Review and Meta-Analysis. Global Spine J. 2018 Dec;8(4 Suppl):49S-58S.		Taylor DG, Buchholz AL, Sure DR, Buell TJ, Nguyen JH, Chen CJ, Diamond JM, Washburn PA, Harrop J, Shaffrey <span class="mw-lingo-term" data-lingo-term-id="3ba0f40775d6d6ace27ef929f5be3cdf" data-hasqtip="3" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;">CI</span>, Smith JS. Presentation and Outcomes After Medical and Surgical Treatment Versus Medical Treatment Alone of Spontaneous Infectious Spondylodiscitis: A Systematic Literature Review and Meta-Analysis. Global Spine J. 2018 Dec;8(4 Suppl):49S-58S.
Line 215:		Line 214:
	<span style="color: rgb(51, 51, 51)">Tiemann A et al: S2k-Leitlinie Akute und chronische exogene Osteomyelitis langer Röhrenknochen des Erwachsenen 2017. AwMF Register 012/033. Stand 12/2017.</span><span style="color: rgb(51, 51, 51)">Tone A, Nguyen S, Devemy F, et al. Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study. Diabetes Care. 2015;38(2):302-307. doi:10.2337/dc14-1514</span><br />Vossen MG, Gattringer R, Thalhammer F, Militz M, Hischebeth G: 10. Knochen- und Gelenkinfektionen. In: Bodmann K-F, Grabein B, Kresken M et al. Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen - Update 2018. PEG S2k Leitlinie. AwMF-Registernummer 082-006. Stand 25.07.2019. S.228-238.		<span style="color: rgb(51, 51, 51)">Tiemann A et al: S2k-Leitlinie Akute und chronische exogene Osteomyelitis langer Röhrenknochen des Erwachsenen 2017. AwMF Register 012/033. Stand 12/2017.</span><span style="color: rgb(51, 51, 51)">Tone A, Nguyen S, Devemy F, et al. Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study. Diabetes Care. 2015;38(2):302-307. doi:10.2337/dc14-1514</span><br />Vossen MG, Gattringer R, Thalhammer F, Militz M, Hischebeth G: 10. Knochen- und Gelenkinfektionen. In: Bodmann K-F, Grabein B, Kresken M et al. Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen - Update 2018. PEG S2k Leitlinie. AwMF-Registernummer 082-006. Stand 25.07.2019. S.228-238.

	<span style="color: rgb(51, 51, 51)">Vossen MG et al.: Knochen- und Gelenkinfektionen. In: Bodmann et al: S2k Leitlinie</span>		<span style="color: rgb(51, 51, 51)">Vossen MG et al.: Knochen- und Gelenkinfektionen. In: Bodmann et al: S2k Leitlinie</span><br /><span style="color: rgb(51, 51, 51)">Walter G, Kemmerer M, Kappler C, Hoffmann R: Treatment algorithms for chronic osteomyelitis. Dtsch Arztebl Int 2012; 109(14): 257–64. DOI: 10.3238/arztebl.2012.0257</span>

	<br /><span style="color: rgb(51, 51, 51)">Walter G, Kemmerer M, Kappler C, Hoffmann R: Treatment algorithms for chronic osteomyelitis. Dtsch Arztebl Int 2012; 109(14): 257–64. DOI: 10.3238/arztebl.2012.0257</span>


	Yagdiran A, Otto-Lambertz C, Lingscheid <span class="mw-lingo-term" data-lingo-term-id="dd480f25b31ec27223fee2c6edcacb3c" data-hasqtip="4" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;">KM</span>, Sircar K, Samel C, Scheyerer MJ, Zarghooni K, Eysel P, Sobottke R, Jung N, Siewe J. Quality of life and mortality after surgical treatment for vertebral osteomyelitis (VO): a prospective study. Eur Spine J. 2020 Jul 1. doi: 10.1007/s00586-020-06519-z.		Yagdiran A, Otto-Lambertz C, Lingscheid <span class="mw-lingo-term" data-lingo-term-id="dd480f25b31ec27223fee2c6edcacb3c" data-hasqtip="4" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;">KM</span>, Sircar K, Samel C, Scheyerer MJ, Zarghooni K, Eysel P, Sobottke R, Jung N, Siewe J. Quality of life and mortality after surgical treatment for vertebral osteomyelitis (VO): a prospective study. Eur Spine J. 2020 Jul 1. doi: 10.1007/s00586-020-06519-z.

	Zimmerli W. Clinical practice. Vertebral osteomyelitis. N Engl J Med. 2010 Mar 18;362(11):1022-9.		Zimmerli W. Clinical practice. Vertebral osteomyelitis. N Engl J Med. 2010 Mar 18;362(11):1022-9.

imported>Bestem at 22:57, 2 May 2022

2022-05-02T22:57:55Z

Show changes

imported>Bestem at 22:35, 2 May 2022

2022-05-02T22:35:29Z

← Older revision		Revision as of 22:35, 2 May 2022
Line 32:		Line 32:

	Izakovicova P, Borens O, Trampuz A: Periprosthetic joint infection: current concepts and outlook. efort Open Rev 2019; 4 482-494. DOI: 10.1302/2058-5241.4.180092.		Izakovicova P, Borens O, Trampuz A: Periprosthetic joint infection: current concepts and outlook. efort Open Rev 2019; 4 482-494. DOI: 10.1302/2058-5241.4.180092.

	~~{{DGI:Knochen-,_Gelenks-_und_Protheseninfektionen/Diabetischer_Fuß/Quellen}}~~
	~~{{DGI:Knochen-,_Gelenks-_und_Protheseninfektionen/Hämatogene_Osteomyelitis/Quellen}}~~
	~~{{DGI:Knochen-,_Gelenks-_und_Protheseninfektionen/Infektionen_nach_offenen_Frakturen/Quellen}}~~
	~~{{DGI:Knochen-,_Gelenks-_und_Protheseninfektionen/Osteomyelitis_bei_Kindern/Quellen}}~~
	~~{{DGI:Knochen-,_Gelenks-_und_Protheseninfektionen/Periprothetische_Infektionen/Quellen}}~~
	~~{{DGI:Knochen-,_Gelenks-_und_Protheseninfektionen/Septische_Arthritis/Quellen}}~~
	~~{{DGI:Knochen-,_Gelenks-_und_Protheseninfektionen/Spondylodiszitis/Quellen}}~~
	~~<br />~~

imported>Bestem: noc

2022-04-12T20:51:40Z

noc

← Older revision		Revision as of 20:51, 12 April 2022
Line 33:		Line 33:
	Izakovicova P, Borens O, Trampuz A: Periprosthetic joint infection: current concepts and outlook. efort Open Rev 2019; 4 482-494. DOI: 10.1302/2058-5241.4.180092.		Izakovicova P, Borens O, Trampuz A: Periprosthetic joint infection: current concepts and outlook. efort Open Rev 2019; 4 482-494. DOI: 10.1302/2058-5241.4.180092.

			{{DGI:Knochen-,_Gelenks-_und_Protheseninfektionen/Diabetischer_Fuß/Quellen}}
			{{DGI:Knochen-,_Gelenks-_und_Protheseninfektionen/Hämatogene_Osteomyelitis/Quellen}}
			{{DGI:Knochen-,_Gelenks-_und_Protheseninfektionen/Infektionen_nach_offenen_Frakturen/Quellen}}
			{{DGI:Knochen-,_Gelenks-_und_Protheseninfektionen/Osteomyelitis_bei_Kindern/Quellen}}
			{{DGI:Knochen-,_Gelenks-_und_Protheseninfektionen/Periprothetische_Infektionen/Quellen}}
			{{DGI:Knochen-,_Gelenks-_und_Protheseninfektionen/Septische_Arthritis/Quellen}}
			{{DGI:Knochen-,_Gelenks-_und_Protheseninfektionen/Spondylodiszitis/Quellen}}
	<br />		<br />

imported>Bestem at 15:14, 8 January 2022

2022-01-08T15:14:45Z

← Older revision		Revision as of 15:14, 8 January 2022
Line 1:		Line 1:
			Herren C, von der Höh N, Dreimann M. Diagnostik und Therapie der Spondylodiszitis S2k-Leitlinie. AWMF-Registernummer: 151-001Stand: 26.August2020

	# '''Herren C,<span style="mso-spacerun:yes"> </span>von der Höh N, Dreimann M.''' Diagnostik und Therapie der Spondylodiszitis S2k-Leitlinie. AWMF-Registernummer: 151-001Stand: 26.August2020		Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis 2015; 61: e26-46.
	~~# '''~~Berbari EF, Kanj SS, Kowalski TJ, ''et al''.~~'''~~ 2015 Infectious Diseases Society of America (~~'''~~IDSA~~'''~~) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis ~~'''~~2015~~'''~~; ~~'''~~61~~'''~~: e26-46.
	# '''Groll AH, Buchheidt D, Heinz W, Bellmann R, Cornely O, Höhl R, ''et al.''''' S1 Leitlinie Diagnose und Therapie von Candida Infektionen: Gemeinsame Empfehlungen der Deutschsprachigen Mykologischen Gesellschaft (DMykG) und der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG). S1-Leitlinie. AWMF-Registernummer 082 – 005. Stand 07/2020
	# '''Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ'''; ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37. doi: 10.1111/1469-0691.12039. PMID: 23137135.
	# '''Schaberg T, Bauer T, Brinkmann F, Diel R, Feiterna-Sperling C, Haas W, ''et al.''''' Tuberkulose im Erwachsenenalter. S2k-Leitlinie. AWMF-Registernummer 020 – 019. Stand 06/2017
	~~# '''Zimmerli W.''' Clinical practice. Vertebral osteomyelitis. N Engl J Med. 2010 Mar 18;362(11):1022-9.~~
	# '''Thabit AK, Fatani DF, Bamakhrama MS, Barnawi OA, Basudan LO, Alhejaili SF.''' Antibiotic penetration into bone and joints: An updated review. Int J Infect Dis. 2019 Apr;81:128-136. doi: 10.1016/j.ijid.2019.02.005. Epub 2019 Feb 14. PMID: 30772469.
	~~# '''Stammschulte T, Isner C, Kern WV.''' Daptomycin (Cubicin®) – aktuelle Diskussion der Einsatzgebiete und Dosierung. Arzneiverordnung in der Praxis Band 44 Heft 2 April 2017~~
	# '''Seaton RA, Menichetti F, Dalekos G, Beiras-Fernandez A, Nacinovich F, Pathan R, Hamed K.''' Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience. Adv Ther. 2015 Dec;32(12):1192-205. doi: 10.1007/s12325-015-0267-4. Epub 2015 Nov 26. PMID: 26610384; PMCID: PMC4679787.
	# '''Senneville E, Caillon J, Calvet B, Jehl F:''' Towards a definition of daptomycin optimal dose: Lessons learned from experimental and clinical data. Int J Antimicrob Agents 2016; 47: 12-19.
	# '''Malizos K, Sarma J, Seaton RA et al.:''' Daptomycin for the treatment of osteomyelitis and orthopaedic device infections:real-world clinical experience from a European registry. Eur J Clin Microbiol Infect Dis 2016; 35: 111-118.
	# '''Seaton RA, Gonzalez-Ruiz A, Cleveland KO et al.:''' Realworld daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. Ann Clin Microbiol Antimicrob 2016; 15: 18.
	# '''Gould IM, Miró JM, Rybak MJ.''' Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents. 2013 Sep;42(3):202-10. doi: 10.1016/j.ijantimicag.2013.05.005. Epub 2013 Jul 8. PMID: 23845504.
	# '''Lora-Tamayo J, Parra-Ruiz J, Rodriguez-Pardo D, et al.''' High doses of daptomycin (10 mg/kg/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: a comparative study. Diagn Microbiol Infect Dis. 2014;80:66–71.28.
	~~# '''Herrera S, Sorli L, Horcajada JP.''' High-dose daptomycin together with rifampin as salvage therapy for prosthetic joint infections. Med Clin (Barc). 2017;149:223–4.29~~
	# '''Vossen MG, Gattringer R, Thalhammer F, Militz M, Hischebeth G:''' 10. Knochen- und Gelenkinfektionen. In: Bodmann K-F, Grabein B, Kresken M et al. Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen - Update 2018. PEG S2k Leitlinie. AwMF-Registernummer 082-006. Stand 25.07.2019. S.228-238.
	~~# '''Izakovicova P, Borens O, Trampuz A:''' Periprosthetic joint infection: current concepts and outlook. efort Open Rev 2019; 4 482-494. DOI: 10.1302/2058-5241.4.180092~~.

			Groll AH, Buchheidt D, Heinz W, Bellmann R, Cornely O, Höhl R, et al. S1 Leitlinie Diagnose und Therapie von Candida Infektionen: Gemeinsame Empfehlungen der Deutschsprachigen Mykologischen Gesellschaft (DMykG) und der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG). S1-Leitlinie. AWMF-Registernummer 082 – 005. Stand 07/2020

			Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ; ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37. doi: 10.1111/1469-0691.12039. PMID: 23137135.

			Schaberg T, Bauer T, Brinkmann F, Diel R, Feiterna-Sperling C, Haas W, et al. Tuberkulose im Erwachsenenalter. S2k-Leitlinie. AWMF-Registernummer 020 – 019. Stand 06/2017

			Zimmerli W. Clinical practice. Vertebral osteomyelitis. N Engl J Med. 2010 Mar 18;362(11):1022-9.

			Thabit AK, Fatani DF, Bamakhrama MS, Barnawi OA, Basudan LO, Alhejaili SF. Antibiotic penetration into bone and joints: An updated review. Int J Infect Dis. 2019 Apr;81:128-136. doi: 10.1016/j.ijid.2019.02.005. Epub 2019 Feb 14. PMID: 30772469.

			Stammschulte T, Isner C, Kern WV. Daptomycin (Cubicin®) – aktuelle Diskussion der Einsatzgebiete und Dosierung. Arzneiverordnung in der Praxis Band 44 Heft 2 April 2017

			Seaton RA, Menichetti F, Dalekos G, Beiras-Fernandez A, Nacinovich F, Pathan R, Hamed K. Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience. Adv Ther. 2015 Dec;32(12):1192-205. doi: 10.1007/s12325-015-0267-4. Epub 2015 Nov 26. PMID: 26610384; PMCID: PMC4679787.

			Senneville E, Caillon J, Calvet B, Jehl F: Towards a definition of daptomycin optimal dose: Lessons learned from experimental and clinical data. Int J Antimicrob Agents 2016; 47: 12-19.

			Malizos K, Sarma J, Seaton RA et al.: Daptomycin for the treatment of osteomyelitis and orthopaedic device infections:real-world clinical experience from a European registry. Eur J Clin Microbiol Infect Dis 2016; 35: 111-118.

			Seaton RA, Gonzalez-Ruiz A, Cleveland KO et al.: Realworld daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. Ann Clin Microbiol Antimicrob 2016; 15: 18.

			Gould IM, Miró JM, Rybak MJ. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents. 2013 Sep;42(3):202-10. doi: 10.1016/j.ijantimicag.2013.05.005. Epub 2013 Jul 8. PMID: 23845504.

			Lora-Tamayo J, Parra-Ruiz J, Rodriguez-Pardo D, et al. High doses of daptomycin (10 mg/kg/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: a comparative study. Diagn Microbiol Infect Dis. 2014;80:66–71.28.

			Herrera S, Sorli L, Horcajada JP. High-dose daptomycin together with rifampin as salvage therapy for prosthetic joint infections. Med Clin (Barc). 2017;149:223–4.29

			Vossen MG, Gattringer R, Thalhammer F, Militz M, Hischebeth G: 10. Knochen- und Gelenkinfektionen. In: Bodmann K-F, Grabein B, Kresken M et al. Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen - Update 2018. PEG S2k Leitlinie. AwMF-Registernummer 082-006. Stand 25.07.2019. S.228-238.

			Izakovicova P, Borens O, Trampuz A: Periprosthetic joint infection: current concepts and outlook. efort Open Rev 2019; 4 482-494. DOI: 10.1302/2058-5241.4.180092.

	<br />		<br />

imported>Fuhrmanns at 07:35, 6 January 2022

2022-01-06T07:35:08Z

← Older revision		Revision as of 07:35, 6 January 2022
Line 1:		Line 1:
	~~==Quellen==~~

	# '''Herren C,<span style="mso-spacerun:yes"> </span>von der Höh N, Dreimann M.''' Diagnostik und Therapie der Spondylodiszitis S2k-Leitlinie. AWMF-Registernummer: 151-001Stand: 26.August2020		# '''Herren C,<span style="mso-spacerun:yes"> </span>von der Höh N, Dreimann M.''' Diagnostik und Therapie der Spondylodiszitis S2k-Leitlinie. AWMF-Registernummer: 151-001Stand: 26.August2020

imported>Brinkery at 13:39, 17 February 2021

2021-02-17T13:39:05Z

← Older revision		Revision as of 13:39, 17 February 2021
Line 1:		Line 1:
	==Quellen==		==Quellen==

			# '''Herren C,<span style="mso-spacerun:yes"> </span>von der Höh N, Dreimann M.''' Diagnostik und Therapie der Spondylodiszitis S2k-Leitlinie. AWMF-Registernummer: 151-001Stand: 26.August2020
			# '''Berbari EF, Kanj SS, Kowalski TJ, ''et al''.''' 2015 Infectious Diseases Society of America ('''IDSA''') clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis '''2015'''; '''61''': e26-46.
			# '''Groll AH, Buchheidt D, Heinz W, Bellmann R, Cornely O, Höhl R, ''et al.''''' S1 Leitlinie Diagnose und Therapie von Candida Infektionen: Gemeinsame Empfehlungen der Deutschsprachigen Mykologischen Gesellschaft (DMykG) und der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG). S1-Leitlinie. AWMF-Registernummer 082 – 005. Stand 07/2020
			# '''Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ'''; ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37. doi: 10.1111/1469-0691.12039. PMID: 23137135.
			# '''Schaberg T, Bauer T, Brinkmann F, Diel R, Feiterna-Sperling C, Haas W, ''et al.''''' Tuberkulose im Erwachsenenalter. S2k-Leitlinie. AWMF-Registernummer 020 – 019. Stand 06/2017
			# '''Zimmerli W.''' Clinical practice. Vertebral osteomyelitis. N Engl J Med. 2010 Mar 18;362(11):1022-9.
			# '''Thabit AK, Fatani DF, Bamakhrama MS, Barnawi OA, Basudan LO, Alhejaili SF.''' Antibiotic penetration into bone and joints: An updated review. Int J Infect Dis. 2019 Apr;81:128-136. doi: 10.1016/j.ijid.2019.02.005. Epub 2019 Feb 14. PMID: 30772469.
			# '''Stammschulte T, Isner C, Kern WV.''' Daptomycin (Cubicin®) – aktuelle Diskussion der Einsatzgebiete und Dosierung. Arzneiverordnung in der Praxis Band 44 Heft 2 April 2017
			# '''Seaton RA, Menichetti F, Dalekos G, Beiras-Fernandez A, Nacinovich F, Pathan R, Hamed K.''' Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience. Adv Ther. 2015 Dec;32(12):1192-205. doi: 10.1007/s12325-015-0267-4. Epub 2015 Nov 26. PMID: 26610384; PMCID: PMC4679787.
			# '''Senneville E, Caillon J, Calvet B, Jehl F:''' Towards a definition of daptomycin optimal dose: Lessons learned from experimental and clinical data. Int J Antimicrob Agents 2016; 47: 12-19.
			# '''Malizos K, Sarma J, Seaton RA et al.:''' Daptomycin for the treatment of osteomyelitis and orthopaedic device infections:real-world clinical experience from a European registry. Eur J Clin Microbiol Infect Dis 2016; 35: 111-118.
			# '''Seaton RA, Gonzalez-Ruiz A, Cleveland KO et al.:''' Realworld daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. Ann Clin Microbiol Antimicrob 2016; 15: 18.
			# '''Gould IM, Miró JM, Rybak MJ.''' Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents. 2013 Sep;42(3):202-10. doi: 10.1016/j.ijantimicag.2013.05.005. Epub 2013 Jul 8. PMID: 23845504.
			# '''Lora-Tamayo J, Parra-Ruiz J, Rodriguez-Pardo D, et al.''' High doses of daptomycin (10 mg/kg/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: a comparative study. Diagn Microbiol Infect Dis. 2014;80:66–71.28.
			# '''Herrera S, Sorli L, Horcajada JP.''' High-dose daptomycin together with rifampin as salvage therapy for prosthetic joint infections. Med Clin (Barc). 2017;149:223–4.29
			# '''Vossen MG, Gattringer R, Thalhammer F, Militz M, Hischebeth G:''' 10. Knochen- und Gelenkinfektionen. In: Bodmann K-F, Grabein B, Kresken M et al. Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen - Update 2018. PEG S2k Leitlinie. AwMF-Registernummer 082-006. Stand 25.07.2019. S.228-238.
			# '''Izakovicova P, Borens O, Trampuz A:''' Periprosthetic joint infection: current concepts and outlook. efort Open Rev 2019; 4 482-494. DOI: 10.1302/2058-5241.4.180092.


	<br />		<br />

imported>Brinkery: Der Seiteninhalt wurde durch einen anderen Text ersetzt: „==Quellen==
“

2021-02-17T11:58:56Z

Der Seiteninhalt wurde durch einen anderen Text ersetzt: „==Quellen== <br />“

← Older revision		Revision as of 11:58, 17 February 2021
Line 1:		Line 1:
	==Quellen==		==Quellen==

	# '''Herren C,<span class="ve-pasteProtect" style="mso-spacerun:yes" data-ve-attributes="{"style":"mso-spacerun:yes"}"> </span>von der Höh N, Dreimann M.''' Diagnostik und Therapie der Spondylodiszitis S2k-Leitlinie. AWMF-Registernummer: 151-001Stand: 26.August2020
	# '''Berbari EF, Kanj SS, Kowalski TJ, ''et al''.''' 2015 Infectious Diseases Society of America ('''IDSA''') clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis '''2015'''; '''61''': e26-46.
	# '''Groll AH, Buchheidt D, Heinz W, Bellmann R, Cornely O, Höhl R, ''et al.''''' S1 Leitlinie Diagnose und Therapie von Candida Infektionen: Gemeinsame Empfehlungen der Deutschsprachigen Mykologischen Gesellschaft (DMykG) und der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG). S1-Leitlinie. AWMF-Registernummer 082 – 005. Stand 07/2020
	# '''Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ'''; ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37. doi: 10.1111/1469-0691.12039. PMID: 23137135.
	# '''Schaberg T, Bauer T, Brinkmann F, Diel R, Feiterna-Sperling C, Haas W, ''et al.''''' Tuberkulose im Erwachsenenalter. S2k-Leitlinie. AWMF-Registernummer 020 – 019. Stand 06/2017
	~~# '''Zimmerli W.''' Clinical practice. Vertebral osteomyelitis. N Engl J Med. 2010 Mar 18;362(11):1022-9.~~
	# '''Thabit AK, Fatani DF, Bamakhrama MS, Barnawi OA, Basudan LO, Alhejaili SF.''' Antibiotic penetration into bone and joints: An updated review. Int J Infect Dis. 2019 Apr;81:128-136. doi: 10.1016/j.ijid.2019.02.005. Epub 2019 Feb 14. PMID: 30772469.
	~~# '''Stammschulte T, Isner C, Kern WV.''' Daptomycin (Cubicin®) – aktuelle Diskussion der Einsatzgebiete und Dosierung. Arzneiverordnung in der Praxis Band 44 Heft 2 April 2017~~
	# '''Seaton RA, Menichetti F, Dalekos G, Beiras-Fernandez A, Nacinovich F, Pathan R, Hamed K.''' Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience. Adv Ther. 2015 Dec;32(12):1192-205. doi: 10.1007/s12325-015-0267-4. Epub 2015 Nov 26. PMID: 26610384; PMCID: PMC4679787.
	# '''Senneville E, Caillon J, Calvet B, Jehl F:''' Towards a definition of daptomycin optimal dose: Lessons learned from experimental and clinical data. Int J Antimicrob Agents 2016; 47: 12-19.
	# '''Malizos K, Sarma J, Seaton RA et al.:''' Daptomycin for the treatment of osteomyelitis and orthopaedic device infections:real-world clinical experience from a European registry. Eur J Clin Microbiol Infect Dis 2016; 35: 111-118.
	# '''Seaton RA, Gonzalez-Ruiz A, Cleveland KO et al.:''' Realworld daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. Ann Clin Microbiol Antimicrob 2016; 15: 18.
	# '''Gould IM, Miró JM, Rybak MJ.''' Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents. 2013 Sep;42(3):202-10. doi: 10.1016/j.ijantimicag.2013.05.005. Epub 2013 Jul 8. PMID: 23845504.
	# '''Lora-Tamayo J, Parra-Ruiz J, Rodriguez-Pardo D, et al.''' High doses of daptomycin (10 mg/kg/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: a comparative study. Diagn Microbiol Infect Dis. 2014;80:66–71.28.
	~~# '''Herrera S, Sorli L, Horcajada JP.''' High-dose daptomycin together with rifampin as salvage therapy for prosthetic joint infections. Med Clin (Barc). 2017;149:223–4.29~~
	# '''Vossen MG, Gattringer R, Thalhammer F, Militz M, Hischebeth G:''' 10. Knochen- und Gelenkinfektionen. In: Bodmann K-F, Grabein B, Kresken M et al. Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen - Update 2018. PEG S2k Leitlinie. AwMF-Registernummer 082-006. Stand 25.07.2019. S.228-238.
	~~# '''Izakovicova P, Borens O, Trampuz A:''' Periprosthetic joint infection: current concepts and outlook. efort Open Rev 2019; 4 482-494. DOI: 10.1302/2058-5241.4.180092.~~

	<br />		<br />

imported>Bestem: /* Quellen */

2021-01-21T17:28:08Z

Quellen

← Older revision		Revision as of 17:28, 21 January 2021
Line 1:		Line 1:
	== Quellen ==		==Quellen==

			# '''Herren C,<span class="ve-pasteProtect" style="mso-spacerun:yes" data-ve-attributes="{"style":"mso-spacerun:yes"}"> </span>von der Höh N, Dreimann M.''' Diagnostik und Therapie der Spondylodiszitis S2k-Leitlinie. AWMF-Registernummer: 151-001Stand: 26.August2020
			# '''Berbari EF, Kanj SS, Kowalski TJ, ''et al''.''' 2015 Infectious Diseases Society of America ('''IDSA''') clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis '''2015'''; '''61''': e26-46.
			# '''Groll AH, Buchheidt D, Heinz W, Bellmann R, Cornely O, Höhl R, ''et al.''''' S1 Leitlinie Diagnose und Therapie von Candida Infektionen: Gemeinsame Empfehlungen der Deutschsprachigen Mykologischen Gesellschaft (DMykG) und der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG). S1-Leitlinie. AWMF-Registernummer 082 – 005. Stand 07/2020
			# '''Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ'''; ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37. doi: 10.1111/1469-0691.12039. PMID: 23137135.
			# '''Schaberg T, Bauer T, Brinkmann F, Diel R, Feiterna-Sperling C, Haas W, ''et al.''''' Tuberkulose im Erwachsenenalter. S2k-Leitlinie. AWMF-Registernummer 020 – 019. Stand 06/2017
			# '''Zimmerli W.''' Clinical practice. Vertebral osteomyelitis. N Engl J Med. 2010 Mar 18;362(11):1022-9.
			# '''Thabit AK, Fatani DF, Bamakhrama MS, Barnawi OA, Basudan LO, Alhejaili SF.''' Antibiotic penetration into bone and joints: An updated review. Int J Infect Dis. 2019 Apr;81:128-136. doi: 10.1016/j.ijid.2019.02.005. Epub 2019 Feb 14. PMID: 30772469.
			# '''Stammschulte T, Isner C, Kern WV.''' Daptomycin (Cubicin®) – aktuelle Diskussion der Einsatzgebiete und Dosierung. Arzneiverordnung in der Praxis Band 44 Heft 2 April 2017
			# '''Seaton RA, Menichetti F, Dalekos G, Beiras-Fernandez A, Nacinovich F, Pathan R, Hamed K.''' Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience. Adv Ther. 2015 Dec;32(12):1192-205. doi: 10.1007/s12325-015-0267-4. Epub 2015 Nov 26. PMID: 26610384; PMCID: PMC4679787.
			# '''Senneville E, Caillon J, Calvet B, Jehl F:''' Towards a definition of daptomycin optimal dose: Lessons learned from experimental and clinical data. Int J Antimicrob Agents 2016; 47: 12-19.
			# '''Malizos K, Sarma J, Seaton RA et al.:''' Daptomycin for the treatment of osteomyelitis and orthopaedic device infections:real-world clinical experience from a European registry. Eur J Clin Microbiol Infect Dis 2016; 35: 111-118.
			# '''Seaton RA, Gonzalez-Ruiz A, Cleveland KO et al.:''' Realworld daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. Ann Clin Microbiol Antimicrob 2016; 15: 18.
			# '''Gould IM, Miró JM, Rybak MJ.''' Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents. 2013 Sep;42(3):202-10. doi: 10.1016/j.ijantimicag.2013.05.005. Epub 2013 Jul 8. PMID: 23845504.
			# '''Lora-Tamayo J, Parra-Ruiz J, Rodriguez-Pardo D, et al.''' High doses of daptomycin (10 mg/kg/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: a comparative study. Diagn Microbiol Infect Dis. 2014;80:66–71.28.
			# '''Herrera S, Sorli L, Horcajada JP.''' High-dose daptomycin together with rifampin as salvage therapy for prosthetic joint infections. Med Clin (Barc). 2017;149:223–4.29
			# '''Vossen MG, Gattringer R, Thalhammer F, Militz M, Hischebeth G:''' 10. Knochen- und Gelenkinfektionen. In: Bodmann K-F, Grabein B, Kresken M et al. Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen - Update 2018. PEG S2k Leitlinie. AwMF-Registernummer 082-006. Stand 25.07.2019. S.228-238.
			# '''Izakovicova P, Borens O, Trampuz A:''' Periprosthetic joint infection: current concepts and outlook. efort Open Rev 2019; 4 482-494. DOI: 10.1302/2058-5241.4.180092.

			<br />

imported>Brinkery: Die Seite wurde neu angelegt: „== Quellen ==“

2020-12-12T23:28:47Z

Die Seite wurde neu angelegt: „== Quellen ==“

New page

== Quellen ==